Can we eliminate placebo in ALS clinical trials?

Wilson W. Bryan, Rebecca J. Hoagland, J. Murphy, Carmel Armon, Richard J. Barohn, Jessie C. Goodpasture, Robert G. Miller, Gareth J. Parry, Jack H. Petajan, Mark A. Ross, Scott C. Stromatt, Jerry M. Belsh, Aron S. Buchman, Peter D. Donofrio, Andrew A. Eisen, Richard A. Gan, Laurie Gutmann, Steven H. Horowitz, Carlayne E. Jackon, Wendy S. JohnstonJohn J. Kelly, Raul N. Mandler, Janice M. Massey, Dawn McGuire, Daniel S. Newman, Robert M. Pascuzzi, Jack H. Petajan, Lawrence H. Phillips, Michael H. Rivner, Mark A. Rubin, Louis S. Russo, Stephen M. Sergay, Austin J. Sumner, Michael R. Swenson, Lawrence Teitel

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)11-15
Number of pages5
JournalAmyotrophic Lateral Sclerosis and Other Motor Neuron Disorders
Volume4
Issue number1
DOIs
StatePublished - Apr 2003

ASJC Scopus Subject Areas

  • Clinical Neurology

Keywords

  • Amyotrophic lateral sclerosis
  • Motor neuron disease
  • Natural history
  • Neuromuscular diseases
  • Placebo

Cite this